Vifor Pharma acquires the Swiss firm Inositec, a clinical stage biopharmaceutical company which is developing first-in-class treatments for unmet medical need. Through this acquisitions, Vifor Pharma will be spearheading the vascular calcification field to improve
Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals. The acquisition broadens Novaremed’s existing pipeline by adding both
EnBiotix, a Boston-based biotech company focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. A merger agreement under which Polyphor will use all of EnBiotix’s outstanding share capital in
Combioxin, a clinical phase biotechnology company based in Epalinges, Switzerland, has signed a worldwide commercial license agreement with Eagle Pharmaceuticals, a fully integrated pharmaceutical company based in Woodcliff Lake, NY, USA. Under the terms of
The team included Christian Wyss (Partner, Corporate / M&A - pictured), Luzius Zumstein (Senior Associate, Corporate / M&A) and Dario Glauser (Trainee, Corporate / M&A).
FoRx Therapeutics, a Basel-based biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress (DRS) pathways activated in cancer, completes a EUR 10M seed-financing round
